Loading clinical trials...
Loading clinical trials...
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Multi-site, Proof of Concept Trial to Evaluate the Efficacy and Safety of LEO 138559 in Adult Subjects With Moderate to Severe Atopic Dermatitis (AD).
Conditions
Interventions
LEO 138559
LEO 138559 placebo
Locations
17
United States
LEO Pharma Investigational Site
Birmingham, Alabama, United States
LEO Pharma Investigational Site
Fountain Valley, California, United States
LEO Pharma Investigational Site
Los Angeles, California, United States
LEO Pharma Investigational Site
Doral, Florida, United States
LEO Pharma Investigational Site
Hialeah, Florida, United States
LEO Pharma Investigational Site
Markham, Ontario, Canada
Start Date
July 14, 2021
Primary Completion Date
June 2, 2022
Completion Date
September 26, 2022
Last Updated
March 13, 2025
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
NCT07265479
Lead Sponsor
LEO Pharma
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions